| scholarly article | Q13442814 |
| P50 | author | Thomas Thatcher | Q42885563 |
| P2093 | author name string | Patricia J Sime | |
| Richard P Phipps | |||
| Denise M Ray | |||
| Heather F Lakatos | |||
| Heather A Burgess | |||
| Louis Eugene Daugherty | |||
| Michelle Redonnet | |||
| P2860 | cites work | Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays | Q25939005 |
| Smads: transcriptional activators of TGF-beta responses | Q28292325 | ||
| The PPARs: from orphan receptors to drug discovery | Q28371618 | ||
| 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma | Q29615221 | ||
| An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) | Q29615693 | ||
| A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation | Q29619212 | ||
| TGF-beta signaling and the fibrotic response | Q29620099 | ||
| Pathogenetic mechanisms in usual interstitial pneumonia/idiopathic pulmonary fibrosis. | Q33607363 | ||
| Thiazolidinediones: a new class of antidiabetic drugs | Q33607634 | ||
| The past and present of pneumoconioses | Q33878127 | ||
| Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation | Q34088380 | ||
| Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment | Q34254594 | ||
| Peroxisome proliferator-activated receptors in inflammation control | Q34262753 | ||
| Prostaglandins as modulators of immunity | Q34543566 | ||
| Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis | Q34764285 | ||
| The myofibroblast in pulmonary fibrosis | Q35022198 | ||
| Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation | Q35128478 | ||
| The role of transforming growth factor beta in lung development and disease | Q35652666 | ||
| 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. | Q35698498 | ||
| Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts | Q36232642 | ||
| Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung | Q37370914 | ||
| Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis | Q37558464 | ||
| Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells | Q38346577 | ||
| Peroxisome proliferator-activated receptor-gamma-independent repression of collagenase gene expression by 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and prostaglandin 15-deoxy-delta(12,14) J2: a role for Smad signaling | Q40595847 | ||
| A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. | Q40657052 | ||
| Differences in the fibrogenic response after transfer of active transforming growth factor-beta1 gene to lungs of "fibrosis-prone" and "fibrosis-resistant" mouse strains | Q40714048 | ||
| Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue | Q41434332 | ||
| Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin | Q43545284 | ||
| Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation | Q44716855 | ||
| Binding analyses between Human PPARgamma-LBD and ligands | Q44724598 | ||
| Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb | Q47070747 | ||
| Aryl hydrocarbon receptor activation in genital tubercle, palate, and other embryonic tissues in 2,3,7, 8-tetrachlorodibenzo-p-dioxin-responsive lacZ mice | Q47680020 | ||
| P433 | issue | 6 | |
| P921 | main subject | pulmonary fibrosis | Q32446 |
| P304 | page(s) | L1146-53 | |
| P577 | publication date | 2005-02-25 | |
| P1433 | published in | American Journal of Physiology - Lung Cellular and Molecular Physiology | Q4352992 |
| P1476 | title | PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis | |
| P478 | volume | 288 |
| Q40996271 | 15-Deoxy-Delta-12,14-Prostaglandin J2 Inhibits Lung Inflammation and Remodeling in Distinct Murine Models of Asthma |
| Q92996418 | 15-Deoxy-∆-12,14-Prostaglandin J2 (15d-PGJ2), an Endogenous Ligand of PPAR-γ: Function and Mechanism |
| Q33380951 | 15-deoxy-delta12,14-PGJ2 enhances platelet production from megakaryocytes |
| Q50501706 | 15-deoxy-Δ12,14 -prostaglandin J2 reduces recruitment of bone marrow-derived monocyte/macrophages in chronic liver injury in mice. |
| Q37000533 | 15-hydroxyprostaglandin dehydrogenase-derived 15-keto-prostaglandin E2 inhibits cholangiocarcinoma cell growth through interaction with peroxisome proliferator-activated receptor-γ, SMAD2/3, and TAP63 proteins |
| Q37690304 | A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility |
| Q33637862 | A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses |
| Q64093835 | Ability to Suppress TGF-β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions |
| Q49917965 | Activated human T lymphocytes inhibit TGFβ-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2. |
| Q34210856 | Activation of PPARs α, β/δ, and γ Impairs TGF-β1-Induced Collagens' Production and Modulates the TIMP-1/MMPs Balance in Three-Dimensional Cultured Chondrocytes. |
| Q53586587 | Activation of mouse and human peroxisome proliferator-activated receptors (alpha, beta/delta, gamma) by perfluorooctanoic acid and perfluorooctane sulfonate. |
| Q89572849 | Adipocyte-specific Repression of PPAR-gamma by NCoR Contributes to Scleroderma Skin Fibrosis |
| Q36734442 | Agonists at PPAR-gamma suppress angiotensin II-induced production of plasminogen activator inhibitor-1 and extracellular matrix in rat cardiac fibroblasts |
| Q41222578 | Alternative strategies to manipulate fibrocyte involvement in the fibrotic tissue response: pharmacokinetic inhibition and the feasibility of directed-adipogenic differentiation |
| Q43075944 | An essential role for fibronectin extra type III domain A in pulmonary fibrosis. |
| Q91387243 | Analyses of alveolar epithelial injury via lipid-related stress in mammalian target of rapamycin inhibitor-induced lung disease |
| Q33776469 | Anti-fibrogenic effect of PPAR-γ agonists in human intestinal myofibroblasts |
| Q39771067 | Antifibrotic effect by activation of peroxisome proliferator-activated receptor-gamma in corneal fibroblasts |
| Q46921305 | Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats |
| Q64245578 | Bronchopulmonary Dysplasia: Crosstalk Between PPARγ, WNT/β-Catenin and TGF-β Pathways; The Potential Therapeutic Role of PPARγ Agonists |
| Q58757982 | Cardiac fibrosis: new insights into the pathogenesis |
| Q46761383 | Conjugated linoleic acid isomers inhibit platelet-derived growth factor-induced NF-kappaB transactivation and collagen formation in human vascular smooth muscle cells |
| Q35170133 | Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma |
| Q33840489 | Curcumin inhibits fibrosis-related effects in IPF fibroblasts and in mice following bleomycin-induced lung injury |
| Q61444815 | Curcumin inhibits the TGF-β1-dependent differentiation of lung fibroblasts via PPARγ-driven upregulation of cathepsins B and L |
| Q37280692 | Curcumin is not a ligand for peroxisome proliferator-activated receptor-γ |
| Q27691806 | Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy. |
| Q37540435 | DHEA and frontal fibrosing alopecia: molecular and physiopathological mechanisms |
| Q37594222 | Determinants of initiation and progression of idiopathic pulmonary fibrosis |
| Q33632171 | Differential expression of transforming growth factor-beta isoforms in bullous keratopathy corneas |
| Q28583062 | Differential induction of PPAR-gamma by luminal glutamine and iNOS by luminal arginine in the rodent postischemic small bowel |
| Q35927929 | Differential β3 Integrin Expression Regulates the Response of Human Lung and Cardiac Fibroblasts to Extracellular Matrix and Its Components |
| Q36369940 | Dynamic regulation of platelet-derived growth factor receptor α expression in alveolar fibroblasts during realveolarization |
| Q33748854 | Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. |
| Q33847144 | Efficacies of rosiglitazone and retinoin on bleomycin-induced pulmonary fibrosis in rats |
| Q35101448 | Electrophilic PPARγ Ligands Attenuate IL-1β and Silica-Induced Inflammatory Mediator Production in Human Lung Fibroblasts via a PPARγ-Independent Mechanism |
| Q40430999 | Electrophilic PPARγ ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: a potentially novel therapy for corneal scarring |
| Q38355897 | Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. |
| Q36063833 | Emerging PPARγ-Independent Role of PPARγ Ligands in Lung Diseases |
| Q37742662 | Fatty Acids of CLA-Enriched Egg Yolks Can Induce Transcriptional Activation of Peroxisome Proliferator-Activated Receptors in MCF-7 Breast Cancer Cells |
| Q64226671 | Frontal fibrosing alopecia: An update on the hypothesis of pathogenesis and treatment |
| Q57784524 | HDAC8 inhibition ameliorates pulmonary fibrosis |
| Q38046124 | Hanging in the balance: endogenous anti-inflammatory mechanisms in tissue repair and fibrosis |
| Q42784201 | Human lung fibroblasts produce proresolving peroxisome proliferator-activated receptor-γ ligands in a cyclooxygenase-2-dependent manner |
| Q35087009 | Hypoxia-induced inhibition of lung development is attenuated by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone |
| Q38014555 | Identifying and testing potential new anti-asthma agents |
| Q53625179 | Increased bleomycin-induced lung injury in mice deficient in the transcription factor T-bet. |
| Q33799573 | Inhibition of transglutaminase 2, a novel target for pulmonary fibrosis, by two small electrophilic molecules |
| Q42726120 | Insulin resistance and hepatitis C. |
| Q35106452 | Integrating mechanisms of pulmonary fibrosis |
| Q47109594 | Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis |
| Q41770246 | Intrinsic defence capacity and therapeutic potential of natriuretic peptides in pulmonary hypertension associated with lung fibrosis |
| Q34416422 | Involvement of PPAR nuclear receptors in tissue injury and wound repair |
| Q54601910 | Involvement of mitogen-activated protein kinase activation in cyclooxygenase-2 and transforming growth factor-β production in alveolar macrophage from chronic bronchitis rats. |
| Q34897476 | Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension? |
| Q89100677 | Joint contracture is reduced by intra-articular implantation of rosiglitazone-loaded hydrogels in a rabbit model of arthrofibrosis |
| Q51435084 | Kynurenine Modulates MMP-1 and Type-I Collagen Expression Via Aryl Hydrocarbon Receptor Activation in Dermal Fibroblasts. |
| Q35694487 | Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-γ |
| Q36245922 | Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker? |
| Q39629362 | Loss of PPARγ expression by fibroblasts enhances dermal wound closure |
| Q36347076 | Macrophage peroxisome proliferator-activated receptor γ deficiency delays skin wound healing through impairing apoptotic cell clearance in mice |
| Q46028248 | Master regulators in primary skin fibroblast fate reprogramming in a human ex vivo model of chronic wounds. |
| Q44876003 | Mechanisms of carbon nanotube-induced pulmonary fibrosis: a physicochemical characteristic perspective |
| Q37350430 | Mechanobiology of adult and stem cells |
| Q91665346 | Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis |
| Q33877294 | MicroRNAs are potential therapeutic targets in fibrosing kidney disease: lessons from animal models |
| Q27026545 | MicroRNAs as potential therapeutic targets in kidney disease |
| Q37847515 | Molecular cross-regulation between PPAR-γ and other signaling pathways: implications for lung cancer therapy. |
| Q34159037 | Muscle gene expression patterns in human rotator cuff pathology. |
| Q37921386 | Myofibroblast differentiation and survival in fibrotic disease |
| Q27022840 | Myofibroblasts |
| Q34512881 | Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages |
| Q34032853 | Nrf2-regulated PPAR{gamma} expression is critical to protection against acute lung injury in mice |
| Q97643663 | Oral administration of curcumin ameliorates pulmonary fibrosis in mice through 15d-PGJ2-mediated induction of hepatocyte growth factor in the colon |
| Q92642118 | PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state |
| Q37681630 | PPAR Agonists for the Prevention and Treatment of Lung Cancer |
| Q36772391 | PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes |
| Q46252518 | PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta |
| Q46830543 | PPAR-gamma agonists inhibit profibrotic phenotypes in human lung fibroblasts and bleomycin-induced pulmonary fibrosis |
| Q33799182 | PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis |
| Q35458969 | PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. |
| Q49953684 | PPARs: Key Regulators of Airway Inflammation and Potential Therapeutic Targets in Asthma. |
| Q36200396 | PPARγ Ligands Regulate Noncontractile and Contractile Functions of Airway Smooth Muscle: Implications for Asthma Therapy |
| Q36605155 | PPARγ activation following apoptotic cell instillation promotes resolution of lung inflammation and fibrosis via regulation of efferocytosis and proresolving cytokines |
| Q28068114 | PPARγ as a Novel Therapeutic Target in Lung Cancer |
| Q33745028 | PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis |
| Q37183230 | Peroxisome Proliferator-Activated Receptor γ Activity is Required for Appropriate Cardiomyocyte Differentiation |
| Q39780799 | Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease |
| Q33816291 | Peroxisome proliferator-activated receptor (PPAR)gamma can inhibit chronic renal allograft damage |
| Q42210954 | Peroxisome proliferator-activated receptor gamma ligands enhance human B cell antibody production and differentiation |
| Q34998187 | Peroxisome proliferator-activated receptor gamma ligands inhibit transforming growth factor-beta-induced, hyaluronan-dependent, T cell adhesion to orbital fibroblasts |
| Q35102314 | Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entry |
| Q35954579 | Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis |
| Q33863173 | Peroxisome proliferator-activated receptor-g agonist treatment increases septation and angiogenesis and decreases airway hyperresponsiveness in a model of experimental neonatal chronic lung disease. |
| Q37326935 | Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator |
| Q36687379 | Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease |
| Q37421267 | Peroxisome proliferator-activated receptor-gamma ligands induce heme oxygenase-1 in lung fibroblasts by a PPARgamma-independent, glutathione-dependent mechanism |
| Q38489705 | Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics? |
| Q37959975 | Peroxisome proliferator-activated receptors (PPARs) in dermatology: Challenge and promise |
| Q80821163 | Peroxisome proliferator-activated receptors and acute lung injury |
| Q36417658 | Peroxisome proliferator-activated receptors in lung cancer. |
| Q36345864 | Pharmacologic inhibition of lactate production prevents myofibroblast differentiation |
| Q39624471 | Pioglitazone inhibits TGFβ induced keratocyte transformation to myofibroblast and extracellular matrix production. |
| Q37864123 | Possible strategies for anti-fibrotic drug intervention in scleroderma |
| Q38842130 | Predicting pulmonary fibrosis in humans after exposure to multi-walled carbon nanotubes (MWCNTs). |
| Q55029093 | Prevention and treatment of bleomycin-induced pulmonary fibrosis with the lactate dehydrogenase inhibitor gossypol. |
| Q37693531 | Proteasomal regulation of pulmonary fibrosis |
| Q26863751 | Recent developments in myofibroblast biology: paradigms for connective tissue remodeling |
| Q36093802 | Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis |
| Q36591722 | Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? |
| Q51585441 | Regulation of myofibroblast transdifferentiation by DNA methylation and MeCP2: implications for wound healing and fibrogenesis. |
| Q39807254 | Relaxin signaling activates peroxisome proliferator-activated receptor gamma |
| Q34593997 | Role of Smad2/3 and p38 MAP kinase in TGF-β1-induced epithelial-mesenchymal transition of pulmonary epithelial cells |
| Q37182794 | Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies |
| Q26786042 | Roles of Proteoglycans and Glycosaminoglycans in Wound Healing and Fibrosis |
| Q37071874 | Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma |
| Q43223419 | Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts |
| Q54331126 | Rosiglitazone attenuates activation of human Tenon's fibroblasts induced by transforming growth factor-β1. |
| Q46961426 | Rosiglitazone increases matrix production and quenches inflammation: studies in human cells. |
| Q33929299 | Serial micro-CT assessment of the therapeutic effects of rosiglitazone in a bleomycin-induced lung fibrosis mouse model |
| Q41833192 | Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo |
| Q91897242 | TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts |
| Q37447470 | Targeting PPAR receptors in the airway for the treatment of inflammatory lung disease |
| Q90242473 | Targeting metabolic dysregulation for fibrosis therapy |
| Q26865930 | The Contribution of Peroxisome Proliferator-Activated Receptor Gamma to Cutaneous Wound Healing |
| Q34294854 | The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation |
| Q33792164 | The PDE1A-PKCalpha signaling pathway is involved in the upregulation of alpha-smooth muscle actin by TGF-beta1 in adventitial fibroblasts |
| Q35503543 | The PPARγ Agonist Rosiglitazone Is Antifibrotic for Scleroderma Lung Fibroblasts: Mechanisms of Action and Differential Racial Effects |
| Q38524619 | The Role of PPAR Gamma in Systemic Sclerosis |
| Q35925362 | The Role of PPARs in Lung Fibrosis |
| Q34805707 | The aryl hydrocarbon receptor ligand ITE inhibits TGFβ1-induced human myofibroblast differentiation |
| Q38341507 | The role of PPARγ-mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology |
| Q41890316 | The scientific basis for novel treatments of systemic sclerosis |
| Q38744473 | The stellate cell system (vitamin A-storing cell system). |
| Q36676619 | The synthetic peroxisome proliferator-activated receptor-gamma agonist ciglitazone attenuates neuroinflammation and accelerates encapsulation in bacterial brain abscesses |
| Q21559629 | The triterpenoid CDDO-Me inhibits bleomycin-induced lung inflammation and fibrosis |
| Q27014616 | The wound healing, chronic fibrosis, and cancer progression triad |
| Q34935981 | Topical rosiglitazone is an effective anti-scarring agent in the cornea. |
| Q64235758 | Transcriptome network analysis identifies protective role of the LXR/SREBP-1c axis in murine pulmonary fibrosis |
| Q38720663 | Transforming growth factor β suppresses peroxisome proliferator-activated receptor γ expression via both SMAD binding and novel TGF-β inhibitory elements. |
| Q47659553 | Transforming growth factor-beta1 induces transdifferentiation of fibroblasts into myofibroblasts in hypoxic pulmonary vascular remodeling |
| Q35527871 | Transglutaminase 2 and its role in pulmonary fibrosis. |
| Q34321160 | Troglitazone attenuates TGF-β1-induced EMT in alveolar epithelial cells via a PPARγ-independent mechanism. |
| Q36478992 | Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells |
Search more.